3.《Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer》 4.《Durvalumab lengthens survival in patients with NSCLC》
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.doi:10.1200/JCO.2023.41.16_suppl.8518218518#Background:First-line durvalumab in extensive-stage small-cell lung cancer (ES-SCLC) ...
局限期小细胞肺癌子宫癌晚期子宫内膜癌+ [177] 非在研适应症 急性髓性白血病大肠腺癌肺腺癌+ [60] 原研机构 AstraZeneca UK Ltd. 在研机构 AstraZeneca PLCMedImmune LLCEli Lilly & Co. + [17] 非在研机构 Circio Holding ASAFred Hutchinson Cancer Research CenterPlexxikon, Inc. ...
The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D +CT) and durvalumab plus chemotherapy (D+CT) versus chemotherapy alone (CT) in firstline metastatic non–small-cell lung cancer (mNSCLC). 开放标签的3期POSEIDON研究在转移性非小细胞肺癌(mNSCLC)...
约1/3的非小细胞肺癌 (non-small cell lung cancer ,NSCLC) 患者在诊断时患有 III 期局部晚期疾病。铂类放化疗是不可切除的 III 期NSCLC的标准治疗方法。接受放化疗的患者的中位无进展生存期很差。作为不能手术的 III 期NSCLC同步放化疗(concurrent chemoradiotherapy,cCRT)后的免疫加强巩固治疗,durvalumab 可以增...
(administered on day 1 of each cycle). Patients received up to four cycles of platinum–etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum–...
(nonsquamous); gemcitabine + carboplatin/cisplatin (squamous); or nab-paclitaxel + carboplatin (either histology). Starting in Week 12, nonsquamous patients who received pemetrexed as part of the first-line regimen can continue pemetrexed maintenance Q4W until disease progression or intolerable ...
The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer. Durvalumab (Imfinzi) plus chemotherapy and bevacizumab (Avastin), followed by maintenance with ...
Durvalumab in combination with oleclumab reduced the risk of non-small cell lung cancer disease progression or death by 56%, whereas patients receiving durvalumab and monalizumab had a 35% reduction.
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients With PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung Trastuzumab Deruxtecan in Patients With HER2+ Advanced/Metastatic Breast Cancer With or Without Brain Metastases: DESTINY-Breast12 Primary Results ...